Marie Bleakley1,2, Alison Sehgal3,4, Stuart Seropian5, Melinda A Biernacki1,6, Elizabeth F Krakow1,6, Ann Dahlberg1,2, Heather Persinger1, Barbara Hilzinger1, Paul J Martin1,6, Paul A Carpenter1,2, Mary E Flowers1,6, Jenna Voutsinas1, Theodore A Gooley1,7, Keith Loeb1,8, Brent L Wood1,9, Shelly Heimfeld1, Stanley R Riddell1,6, Warren D Shlomchik3,4,10,11. 1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 2. Department of Pediatrics, University of Washington, Seattle, WA. 3. UPMC Hillman Cancer Center, Pittsburgh, PA. 4. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA. 5. Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, CT. 6. Department of Medicine, University of Washington, Seattle, WA. 7. Department of Biostatistics, University of Washington School of Public Health, Seattle, WA. 8. Department of Pathology, University of Washington, Seattle, WA. 9. Division of Hematopathology, Department of Laboratory Medicine, University of Washington, Seattle, WA. 10. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA. 11. The Starzl Transplantation Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Abstract
PURPOSE: Graft-versus-host disease (GVHD) causes morbidity and mortality following allogeneic hematopoietic cell transplantation. Naive T cells (TN) cause severe GVHD in murine models. We evaluated chronic GVHD (cGVHD) and other outcomes in three phase II clinical trials of TN-depletion of peripheral blood stem-cell (PBSC) grafts. METHODS: One hundred thirty-eight patients with acute leukemia received TN-depleted PBSC from HLA-matched related or unrelated donors following conditioning with high- or intermediate-dose total-body irradiation and chemotherapy. GVHD prophylaxis was with tacrolimus, with or without methotrexate or mycophenolate mofetil. Subjects received CD34-selected PBSC and a defined dose of memory T cells depleted of TN. Median follow-up was 4 years. The primary outcome of the analysis of cumulative data from the three trials was cGVHD. RESULTS: cGVHD was very infrequent and mild (3-year cumulative incidence total, 7% [95% CI, 2 to 11]; moderate, 1% [95% CI, 0 to 2]; severe, 0%). Grade III and IV acute GVHD (aGVHD) occurred in 4% (95% CI, 1 to 8) and 0%, respectively. The cumulative incidence of grade II aGVHD, which was mostly stage 1 upper gastrointestinal GVHD, was 71% (95% CI, 64 to 79). Recipients of matched related donor and matched unrelated donor grafts had similar rates of grade III aGVHD (5% [95% CI, 0 to 9] and 4% [95% CI, 0 to 9]) and cGVHD (7% [95% CI, 2 to 13] and 6% [95% CI, 0 to 12]). Overall survival, cGVHD-free, relapse-free survival, relapse, and nonrelapse mortality were, respectively, 77% (95% CI, 71 to 85), 68% (95% CI, 61 to 76), 23% (95% CI, 16 to 30), and 8% (95% CI, 3 to 13) at 3 years. CONCLUSION: Depletion of TN from PBSC allografts results in very low incidences of severe acute and any cGVHD, without apparent excess risks of relapse or nonrelapse mortality, distinguishing this novel graft engineering strategy from other hematopoietic cell transplantation approaches.
PURPOSE: Graft-versus-host disease (GVHD) causes morbidity and mortality following allogeneic hematopoietic cell transplantation. Naive T cells (TN) cause severe GVHD in murine models. We evaluated chronic GVHD (cGVHD) and other outcomes in three phase II clinical trials of TN-depletion of peripheral blood stem-cell (PBSC) grafts. METHODS: One hundred thirty-eight patients with acute leukemia received TN-depleted PBSC from HLA-matched related or unrelated donors following conditioning with high- or intermediate-dose total-body irradiation and chemotherapy. GVHD prophylaxis was with tacrolimus, with or without methotrexate or mycophenolate mofetil. Subjects received CD34-selected PBSC and a defined dose of memory T cells depleted of TN. Median follow-up was 4 years. The primary outcome of the analysis of cumulative data from the three trials was cGVHD. RESULTS: cGVHD was very infrequent and mild (3-year cumulative incidence total, 7% [95% CI, 2 to 11]; moderate, 1% [95% CI, 0 to 2]; severe, 0%). Grade III and IV acute GVHD (aGVHD) occurred in 4% (95% CI, 1 to 8) and 0%, respectively. The cumulative incidence of grade II aGVHD, which was mostly stage 1 upper gastrointestinal GVHD, was 71% (95% CI, 64 to 79). Recipients of matched related donor and matched unrelated donor grafts had similar rates of grade III aGVHD (5% [95% CI, 0 to 9] and 4% [95% CI, 0 to 9]) and cGVHD (7% [95% CI, 2 to 13] and 6% [95% CI, 0 to 12]). Overall survival, cGVHD-free, relapse-free survival, relapse, and nonrelapse mortality were, respectively, 77% (95% CI, 71 to 85), 68% (95% CI, 61 to 76), 23% (95% CI, 16 to 30), and 8% (95% CI, 3 to 13) at 3 years. CONCLUSION: Depletion of TN from PBSC allografts results in very low incidences of severe acute and any cGVHD, without apparent excess risks of relapse or nonrelapse mortality, distinguishing this novel graft engineering strategy from other hematopoietic cell transplantation approaches.
Authors: Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg Journal: J Clin Invest Date: 2017-01-09 Impact factor: 14.808
Authors: Robert J Soiffer; Haesook T Kim; Joseph McGuirk; Mitchell E Horwitz; Laura Johnston; Mrinal M Patnaik; Witold Rybka; Andrew Artz; David L Porter; Thomas C Shea; Michael W Boyer; Richard T Maziarz; Paul J Shaughnessy; Usama Gergis; Hana Safah; Ran Reshef; John F DiPersio; Patrick J Stiff; Madhuri Vusirikala; Jeff Szer; Jennifer Holter; James D Levine; Paul J Martin; Joseph A Pidala; Ian D Lewis; Vincent T Ho; Edwin P Alyea; Jerome Ritz; Frank Glavin; Peter Westervelt; Madan H Jagasia; Yi-Bin Chen Journal: J Clin Oncol Date: 2017-10-17 Impact factor: 44.544
Authors: Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: Nicolaus Kröger; Carlos Solano; Christine Wolschke; Giuseppe Bandini; Francesca Patriarca; Massimo Pini; Arnon Nagler; Carmine Selleri; Antonio Risitano; Giuseppe Messina; Wolfgang Bethge; Jaime Pérez de Oteiza; Rafael Duarte; Angelo Michele Carella; Michele Cimminiello; Stefano Guidi; Jürgen Finke; Nicola Mordini; Christelle Ferra; Jorge Sierra; Domenico Russo; Mario Petrini; Giuseppe Milone; Fabio Benedetti; Marion Heinzelmann; Domenico Pastore; Manuel Jurado; Elisabetta Terruzzi; Franco Narni; Andreas Völp; Francis Ayuk; Tapani Ruutu; Francesca Bonifazi Journal: N Engl J Med Date: 2016-01-07 Impact factor: 91.245
Authors: Daisuke Araki; Brent L Wood; Megan Othus; Jerald P Radich; Anna B Halpern; Yi Zhou; Marco Mielcarek; Elihu H Estey; Frederick R Appelbaum; Roland B Walter Journal: J Clin Oncol Date: 2015-12-14 Impact factor: 44.544
Authors: Benjamin Watkins; Muna Qayed; Courtney McCracken; Brandi Bratrude; Kayla Betz; Yvonne Suessmuth; Alison Yu; Shauna Sinclair; Scott Furlan; Steven Bosinger; Victor Tkachev; James Rhodes; Audrey Grizzle Tumlin; Alexandria Narayan; Kayla Cribbin; Scott Gillespie; Ted A Gooley; Marcelo C Pasquini; Kyle Hebert; Urvi Kapoor; Andre Rogatko; Mourad Tighiouart; Sungjin Kim; Catherine Bresee; Sung W Choi; Jeffrey Davis; Christine Duncan; Roger Giller; Michael Grimley; Andrew C Harris; David Jacobsohn; Nahal Lalefar; Maxim Norkin; Nosha Farhadfar; Michael A Pulsipher; Shalini Shenoy; Aleksandra Petrovic; Kirk R Schultz; Gregory A Yanik; Edmund K Waller; John E Levine; James L Ferrara; Bruce R Blazar; Amelia Langston; John T Horan; Leslie S Kean Journal: J Clin Oncol Date: 2021-01-15 Impact factor: 50.717
Authors: Betty K Hamilton; Corey Cutler; Clint Divine; Mark Juckett; Charles LeMaistre; Susan Stewart; Jennifer Wilder; Mary Horowitz; Nandita Khera; Linda J Burns Journal: Transplant Cell Ther Date: 2022-05-09
Authors: Agnes Bonifacius; Sabine Tischer-Zimmermann; Maria Michela Santamorena; Philip Mausberg; Josephine Schenk; Stephanie Koch; Johanna Barnstorf-Brandes; Nina Gödecke; Jörg Martens; Lilia Goudeva; Murielle Verboom; Jana Wittig; Britta Maecker-Kolhoff; Herrad Baurmann; Caren Clark; Olaf Brauns; Martina Simon; Peter Lang; Oliver A Cornely; Michael Hallek; Rainer Blasczyk; Dominic Seiferling; Philipp Köhler; Britta Eiz-Vesper Journal: Front Bioeng Biotechnol Date: 2022-04-04